Carisma receives Nasdaq delisting notice for bid price non-compliance; schedules Aug 5 reverse split vote

Carisma Therapeutics Inc.

Nasdaq notified Carisma on July 9, 2025 that failure to regain bid price compliance is an additional delisting basis.
Listing transferred to Nasdaq Capital Market on June 12, 2025 with exception through Oct 7, 2025 to show compliance.
Special meeting set for Aug 5, 2025 to approve reverse stock split (1:10 to 1:50) to increase bid price.
No assurance reverse split will achieve compliance or Panel terms will be met by Oct 7, 2025.

item 3.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.